Percentage of subjects with no heavy drinking days: Evaluation as an efficacy endpoint for alcohol clinical trials

Alcoholism: Clinical and Experimental Research

Volumn 34, Issue 12, 2010, Pages 2022-2034

  Falk, Daniel ^a   Wang, Xin Qun ^b   Liu, Lei ^b   Fertig, Joanne ^a   Mattson, Margaret ^a   Ryan, Megan ^a   Johnson, Bankole ^c   Stout, Robert ^d   Litten, Raye Z ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d Pacific Institute for Research and Evaluation   (United States)

Author keywords

Alcohol; COMBINE; Grace Period; Heavy Drinking Days; Naltrexone; Outcome Measure; Topiramate; Treatment End Point

Indexed keywords

ACAMPROSATE; NALTREXONE; PLACEBO; TOPIRAMATE;

ALCOHOLISM; ARTICLE; BEHAVIOR THERAPY; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; CLINICAL RESEARCH; EVALUATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERCENTAGE OF SUBJECTS WITH NO HEAVY DRINKING DAYS; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

ALCOHOL DETERRENTS; ALCOHOL DRINKING; ALCOHOLISM; FEMALE; FRUCTOSE; HUMANS; MALE; NALTREXONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAURINE; TEMPERANCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 78649567596     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2010.01290.x     Document Type: Article

References (20)

1. Allen JP (2003) Measuring outcome in interventions for alcohol dependence and problem drinking: executive summary of a conference sponsored by the National Institute of Alcohol Abuse and Alcoholism. Alcohol Clin Exp Res 27:1657-1660.
2. Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Han J (2008) A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psycholpharmacol 28:5-12.
3. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, CoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence. JAMA 295:2003-2017.
4. Breslow RA, Graubard BI (2008) Prospective study of alcohol consumption in the United States: quantity, frequency, and cause-specific mortality. Alcohol Clin Exp Res 32:513-521.
5. Ciraulo DA, Dong Q, Siverman BL, Gastfriend DR, Pettinati HM (2008) Early treatment response in alcohol dependence with extended-release naltrexone. J Clin Psychiatry 69:190-195.
6. Clifford PR, Maisto SkA, Stout RL, Mckay JR, Tonigan JS (2006) Long-term posttreatment functioning among those treated for alcohol use disorders. Alcohol Clin Exp Res 30:311-319.
7. Cohen J (1992) A power primer. Psychol Bull 112:155-159.
8. Dawson DA, Li TK, Grant BF (2008) A prospective study of risk drinking: at risk for what? Drug Alcohol Depend 95:62-72.
9. Donovan DM, Anton RF, Miller WR, Longabaugh R, Hosking JD, Youngblood M (2008) Combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): examination of posttreatment drinking outcomes. J Stud Alcohol Drugs 69:5-13.
10. FDA (2006) Medical Review of Vivitrol: 21-897. U.S. Government, Rockville, Maryland.
11. Greenfield TM, Bond J, Kerr WC, Nayak MB, Anton RF, Kranzler HR, Kaskutas LA (2005) Risks of Alcohol Use Disorders for treated and concerned individuals are higher than for others at given patterns of drinking. Presented at Annual Epidemiological Symposium of the Kettil Bruun Society for the Epidemiological and Social Research on Alcohol, Riverside, CA, May 30.
12. Jackson KM (2008) Heavy episodic drinking: determining the predictive utility of five or more drinks. Psychol Addict Behav 22:68-77.
13. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM (2007) Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298:1641-1651.
14. Miller WR (1996) Form 90: A Structured Assessment Interview for Drinking and Related Behaviors. Project MATCH Monograph Series. Volume 5, DHHS Pub. No. (NIH) 96-4044.
15. Miller WR, Heather N, Hall W (1991) Calculating standard drink units: international comparisons. Br J Addict 86:43-47.
16. Miller WR, Tonigan JS, Longabaugh R (1995) The Drinker Inventory of Consequences (DrInC): An Instrument for Assessing Adverse Consequences of Alcohol Abuse (Test Manual). Project MATCH Monograph Series. Volume 4, DHHS Pub. No. 95-3911.
17. National Institute on Alcohol Abuse and Alcoholism (2007) Helping Patients Who Drink too Much: A Clinician's Guide, Updated 2005 edition, US. Department of Health & Human Services, National Institutes of Health, Bethesda, MD.
18. Sobell LC, Sobell MB (1992) Timeline followback: a technique for assessing self-reported ethanol consumption, in Measuring Alcohol Consumption: Psychosocial and Biological Methods (Litten RZ, Allen JP eds), pp. 41-72. Humana Press, Totowa, NJ.
19. Witkiewitz KA, Masyn KE (2008) Drinking trajectories following an initial lapse. Psychol Addict Behav 22:157-167.
20. Zweben A, Cisler RA (2003) Clinical and methodological utility of a composite outcome measure for alcohol treatment research. Alcohol Clin Exp Res 27:1680-1685.